Rothschild & Co Redburn Forecasts Strong Price Appreciation for Biogen (NASDAQ:BIIB) Stock

Key Points

• Rothschild & Co Redburn raised its price target on Biogen to $190 and forecast FY2026 EPS of $15.98, though that target implies only about a 0.01% upside from the current share price.
• Analysts are split but leaning neutral overall: 14 Buy, 13 Hold and 1 Sell produce a consensus rating of Hold with an average price target of $213.85.
• Biogen recently beat quarterly estimates with $3.57 EPS (vs. $2.95 expected) and revenue of $2.48B, set FY2026 guidance of 14.25–15.25 EPS, and trades near $189.99 with a market cap around $27.9B.

Biogen (NASDAQ:BIIB - Get Free Report) had its target price raised by investment analysts at Rothschild & Co Redburn from $180.00 to $190.00 in a research report issued on Thursday,MarketScreener reports. Rothschild & Co Redburn's price target points to a potential upside of 0.01% from the stock's current price. Rothschild & Co Redburn also issued estimates for Biogen's FY2026 earnings at $15.98 EPS.

A number of other analysts have also recently commented on the stock. Wells Fargo & Company upped their price objective on shares of Biogen from $190.00 to $200.00 and gave the company an "equal weight" rating in a research report on Sunday, February 8th. Stifel Nicolaus upped their price objective on shares of Biogen from $202.00 to $214.00 and gave the company a "buy" rating in a research report on Friday, February 6th. HSBC upped their price objective on shares of Biogen from $143.00 to $150.00 and gave the company a "reduce" rating in a research report on Tuesday, March 17th. Royal Bank Of Canada upped their price objective on shares of Biogen from $213.00 to $222.00 and gave the company an "outperform" rating in a research report on Thursday. Finally, TD Cowen increased their target price on Biogen from $175.00 to $215.00 and gave the stock a "buy" rating in a report on Monday, February 9th. Fourteen equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $213.85.

Biogen Trading Up 0.4%

Shares of BIIB traded up $0.71 during trading hours on Thursday, reaching $189.99. The stock had a trading volume of 65,672 shares, compared to its average volume of 1,317,165. The company has a quick ratio of 2.03, a current ratio of 3.06 and a debt-to-equity ratio of 0.34. Biogen has a 52 week low of $115.25 and a 52 week high of $202.41. The firm has a 50-day moving average of $184.52 and a 200 day moving average of $176.06. The company has a market cap of $27.88 billion, a P/E ratio of 20.39, a P/E/G ratio of 1.63 and a beta of 0.16.

Biogen (NASDAQ:BIIB - Get Free Report) last released its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, beating analysts' consensus estimates of $2.95 by $0.62. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The business had revenue of $2.48 billion during the quarter, compared to analysts' expectations of $2.29 billion. During the same quarter in the prior year, the company earned $3.02 EPS. The firm's quarterly revenue was up 1.9% on a year-over-year basis. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, sell-side analysts expect that Biogen will post 14.91 earnings per share for the current fiscal year.

Insider Transactions at Biogen

In other Biogen news, insider Priya Singhal sold 2,660 shares of the stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the transaction, the insider owned 8,043 shares in the company, valued at approximately $1,607,232.69. This represents a 24.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.18% of the company's stock.

Hedge Funds Weigh In On Biogen

A number of large investors have recently added to or reduced their stakes in BIIB. Reflection Asset Management acquired a new position in shares of Biogen during the 4th quarter worth about $25,000. WPG Advisers LLC boosted its stake in shares of Biogen by 417.9% during the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company's stock worth $26,000 after buying an additional 117 shares during the last quarter. First Horizon Corp acquired a new position in shares of Biogen during the 4th quarter worth about $30,000. Root Financial Partners LLC boosted its stake in shares of Biogen by 198.4% during the 4th quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company's stock worth $33,000 after buying an additional 123 shares during the last quarter. Finally, MV Capital Management Inc. acquired a new position in shares of Biogen during the 4th quarter worth about $34,000. Institutional investors own 87.93% of the company's stock.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.